Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zai Lab Ltd ADR (NQ: ZLAB )

32.95 +0.46 (+1.42%)
Streaming Delayed Price Updated: 10:41 AM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
Intel, Noah Holdings, Twilio And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping over 250 points on Wednesday. Here are some big stocks recording gains in today’s session. SunCar Technology Group Inc. (NASDAQ: SDA) shares gained... 
Via Benzinga
Zai Lab Announces Participation in June Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Why Shares of Alibaba, PDD, and Zai Lab Are Rising Today
Several Chinese stocks rose today after positive sentiment from Wall Street and recent comments made by President Biden. 
Via The Motley Fool
Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
Zai Lab: Q1 Earnings Insights
 
Via Benzinga
Earnings Preview For Zai Lab
 
Via Benzinga
FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections
 
Via Benzinga
Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Zai Lab's Earnings: A Preview
 
Via Benzinga
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
YL212 expands Zai Lab’s lung cancer franchise and enriches its global oncology pipeline with a potential first-in-class ADC 
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Zai Lab Limited
Via GlobeNewswire
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
New translational and clinical biomarker data from Zai Lab’s global oncology program ZL-1211 will be featured in a poster presentation (Abstract presentation number: 4531) 
From Zai Lab Limited
Via GlobeNewswire
1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off
This company plans to be profitable soon, and its revenue is already spiking. 
Via The Motley Fool
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Zai Lab Limited
Via GlobeNewswire
2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 Years
Biotechs are capable of making huge gains in short periods, and they often do. 
Via The Motley Fool
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts... 
Via Benzinga
2 Stocks That Could Rebound and Rise 30% or More in 2023
They're down, but they aren't yet out. 
Via The Motley Fool
Why Shares of MacroGenics Jumped Thursday
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy. 
Via The Motley Fool
2 Growth Stocks With Incredible Potential in the Next 5 Years
Neither is profitable, but both could be on the verge of massive booms in revenue. 
Via The Motley Fool
Veritone, Samsara, Lexicon Pharmaceuticals And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. 
Via Benzinga
Why Cano Health Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Exela Technologies, Inc. (NASDAQ: XELA) shares surged 45% to $0.0701 after the company announced $51 million of new funding, amendment increases existing securitization facility to $185 million... 
Via Benzinga
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Participation in March Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
From Zai Lab Limited
Via GlobeNewswire
3 More Mid-Cap Biotechs The Street Sees Doubling
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
Via MarketBeat
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
From Zai Lab Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.